MERCK AND MODERNA WILL PRESENT RESULTS FROM LANDMARK PHASE 3 INTERPATH-001 TRIAL FOR INTISMERAN AUTOGENE PLUS KEYTRUDA® (PEMBROLIZUMAB) AT ESMO 2026 PRESIDENTIAL SYMPOSIUM

Reuters · 3d ago

Please log in to view news